{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:05:12Z","timestamp":1751947512622,"version":"3.41.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974003","82370220"],"award-info":[{"award-number":["81974003","82370220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11596-025-00054-y","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:42:52Z","timestamp":1746510172000},"page":"513-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Haploidentical Hematopoietic Stem Cell Transplantation for AML Patients with Persistent Molecular MRD"],"prefix":"10.1007","volume":"45","author":[{"given":"Shan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-wen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-3062","authenticated-orcid":false,"given":"Ling-hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"23","key":"54_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209\u20132221.","journal-title":"N Engl J Med."},{"issue":"12","key":"54_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136\u20131152.","journal-title":"N Engl J Med."},{"issue":"1","key":"54_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/2159-8290.CD-14-0788","volume":"5","author":"CL Chaffer","year":"2015","unstructured":"Chaffer CL, Weinberg RA. How does multistep tumorigenesis truly proceed? Cancer Discov. 2015;5(1):22\u201324.","journal-title":"Cancer Discov."},{"issue":"6","key":"54_CR4","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1158\/1078-0432.CCR-18-1637","volume":"25","author":"M Lv","year":"2019","unstructured":"Lv M, Wang Y, Chang YJ, et al. Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(6):1737\u20131748.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"3","key":"54_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21(3):454\u2013459.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"issue":"7","key":"54_CR6","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/leu.2017.113","volume":"31","author":"CS Hourigan","year":"2017","unstructured":"Hourigan CS, Gale RP, Gormley NJ, et al. Measurable residual disease testing in acute myeloid leukemia. Leukemia. 2017;31(7):1482\u20131490.","journal-title":"Leukemia."},{"issue":"4","key":"54_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u2013447.","journal-title":"Blood."},{"issue":"5","key":"54_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016;374(5):422\u2013433.","journal-title":"N Engl J Med."},{"issue":"12","key":"54_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u20131377.","journal-title":"Blood."},{"issue":"26","key":"54_CR10","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753\u20132767.","journal-title":"Blood."},{"issue":"2","key":"54_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35717","volume":"131","author":"L Wang","year":"2025","unstructured":"Wang L, Chen Y, Zang M, et al. Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia. Cancer. 2025;131(2):e35717.","journal-title":"Cancer."},{"issue":"8","key":"54_CR12","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2015.9452","volume":"314","author":"F Pastore","year":"2015","unstructured":"Pastore F, Levine RL. Next-Generation Sequencing and Detection of Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Clinical Practice? JAMA. 2015;314(8):778\u2013780.","journal-title":"JAMA."},{"issue":"9","key":"54_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","volume":"329","author":"LW Dillon","year":"2023","unstructured":"Dillon LW, Gui G, Page KM, et al. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA. 2023;329(9):745\u2013755.","journal-title":"JAMA."},{"issue":"3","key":"54_CR14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/ajh.26442","volume":"97","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Craddock C, et al. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party\/European society of blood and marrow transplantation. Am J Hematol. 2022;97(3):274\u2013282.","journal-title":"Am J Hematol."},{"issue":"12","key":"54_CR15","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/s41409-021-01475-8","volume":"56","author":"EC Liang","year":"2021","unstructured":"Liang EC, Chen C, Lu R, et al. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(12):3091\u20133093.","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"54_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253386","volume":"16","author":"P K\u00f6vy","year":"2021","unstructured":"K\u00f6vy P, \u0150rfi Z, Bors A, et al. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS ONE. 2021;16(6):e0253386.","journal-title":"PLoS ONE."},{"issue":"1","key":"54_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/asheducation-2017.1.37","volume":"2017","author":"M Moarii","year":"2017","unstructured":"Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematol Am Soc Hematol Educ Program. 2017;2017(1):37\u201344.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"16","key":"54_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132(16):1703\u20131713.","journal-title":"Blood."},{"issue":"2","key":"54_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/cancers11020252","volume":"11","author":"M Leisch","year":"2019","unstructured":"Leisch M, Jansko B, Zaborsky N, et al. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and\/or Modulation? Cancers. 2019;11(2):252.","journal-title":"Cancers."},{"issue":"9","key":"54_CR20","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, Heida B, B\u00fcttner K, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5(9):2294\u20132304.","journal-title":"Blood Adv."},{"issue":"6","key":"54_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","volume":"11","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Kim Y, Kang D, et al. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J. 2021;11(6):109.","journal-title":"Blood Cancer J."},{"issue":"1","key":"54_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41408-023-00833-7","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Solis-Ruiz J, Yang F, et al. NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood Cancer J. 2023;13(1):59.","journal-title":"Blood Cancer J."},{"issue":"5","key":"54_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u2013951.","journal-title":"Blood."},{"key":"54_CR24","doi-asserted-by":"publisher","first-page":"1017850","DOI":"10.3389\/fimmu.2022.1017850","volume":"13","author":"Z Huang","year":"2022","unstructured":"Huang Z, Yan H, Teng Y, et al. Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia. Front Immunol. 2022;13:1017850.","journal-title":"Front Immunol."},{"key":"54_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993419","volume":"13","author":"R Zhang","year":"2022","unstructured":"Zhang R, Lu X, Tang LV, et al. Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation. Front Immunol. 2022;13:993419.","journal-title":"Front Immunol."},{"issue":"10","key":"54_CR26","first-page":"663","volume":"10","author":"R Reshef","year":"2012","unstructured":"Reshef R. Prevention of graft-versus-host disease. Clin Adv Hematol Oncol HO. 2012;10(10):663\u2013665.","journal-title":"Clin Adv Hematol Oncol HO."},{"issue":"24","key":"54_CR27","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1016\/j.scib.2021.06.002","volume":"66","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu QF, Lin R, et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. Sci Bull. 2021;66(24):2498\u20132505.","journal-title":"Sci Bull."},{"issue":"12","key":"54_CR28","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia. 2003;17(12):2318\u20132357.","journal-title":"Leukemia."},{"issue":"4","key":"54_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1200\/JCO.2013.50.5768","volume":"32","author":"M Stelljes","year":"2014","unstructured":"Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(4):288\u2013296.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"13","key":"54_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018;378(13):1189\u20131199.","journal-title":"N Engl J Med."},{"issue":"1","key":"54_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/leu.2017.200","volume":"32","author":"VI Gaidzik","year":"2018","unstructured":"Gaidzik VI, Weber D, Paschka P, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32(1):30\u201337.","journal-title":"Leukemia."},{"issue":"7","key":"54_CR32","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2018","unstructured":"Rothenberg-Thurley M, Amler S, Goerlich D, et al. Persistence of preleukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598\u20131608.","journal-title":"Leukemia."},{"issue":"18","key":"54_CR33","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","volume":"36","author":"K Morita","year":"2018","unstructured":"Morita K, Kantarjian HM, Wang F, et al. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(18):1788\u20131797.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8","key":"54_CR34","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/clinchem\/hvaa119","volume":"66","author":"EN De Boer","year":"2020","unstructured":"De Boer EN, Johansson LF, De Lange K, et al. Detection of Fusion Genes to Determine Minimal Residual Disease in Leukemia Using Next-Generation Sequencing. Clin Chem. 2020;66(8):1084\u20131092.","journal-title":"Clin Chem."},{"issue":"8","key":"54_CR35","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/ajh.25514","volume":"94","author":"RD Press","year":"2019","unstructured":"Press RD, Eickelberg G, Froman A, et al. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol. 2019;94(8):902\u2013912.","journal-title":"Am J Hematol."},{"issue":"5","key":"54_CR36","doi-asserted-by":"publisher","first-page":"606","DOI":"10.5858\/arpa.2017-0229-OA","volume":"142","author":"P Blombery","year":"2018","unstructured":"Blombery P, Jones K, Doig K, et al. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory. Arch Pathol Lab Med. 2018;142(5):606\u2013612.","journal-title":"Arch Pathol Lab Med."},{"issue":"15","key":"54_CR37","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/CM9.0000000000002347","volume":"136","author":"J Liu","year":"2023","unstructured":"Liu J, Wu D, Liu Q, et al. More than two courses of pretransplant consolidation therapy benefits patients with acute myeloid leukemia in the first complete remission who underwent human leukocyte antigen-matched sibling allografts: a multicenter study. Chin Med J (Engl). 2023;136(15):1855.","journal-title":"Chin Med J (Engl)."},{"issue":"3","key":"54_CR38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/bmt.2016.308","volume":"52","author":"F Buccisano","year":"2017","unstructured":"Buccisano F, Maurillo L, Piciocchi A, et al. Pretransplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplant. 2017;52(3):473\u2013475.","journal-title":"Bone Marrow Transplant."},{"issue":"39","key":"54_CR39","doi-asserted-by":"publisher","first-page":"42345","DOI":"10.18632\/oncotarget.5645","volume":"6","author":"H Debarri","year":"2015","unstructured":"Debarri H, Lebon D, Roumier C, et al. IDH1\/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2015;6(39):42345-42353.","journal-title":"Oncotarget."},{"issue":"10","key":"54_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00432-024-05999-6","volume":"150","author":"L Wang","year":"2024","unstructured":"Wang L, Shu M, Zhang Z, et al. Prognostic impact of clonal hematopoiesis mutations at complete molecular remission in acute myeloid leukemia with NPM1 mutation. J Cancer Res Clin Oncol. 2024;150(10):465.","journal-title":"J Cancer Res Clin Oncol."},{"key":"54_CR41","doi-asserted-by":"crossref","unstructured":"Zhang X hui, Chen J, Han MZ, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol OncolJ Hematol Oncol. 2021;14:145.","DOI":"10.1186\/s13045-021-01159-2"},{"issue":"8","key":"54_CR42","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/leu.2014.55","volume":"28","author":"R Kihara","year":"2014","unstructured":"Kihara R, Nagata Y, Kiyoi H, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28(8):1586\u20131595.","journal-title":"Leukemia."},{"issue":"12","key":"54_CR43","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","volume":"3","author":"A Rashidi","year":"2019","unstructured":"Rashidi A, Hamadani M, Zhang MJ, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826-1836.","journal-title":"Blood Adv."},{"issue":"Suppl 2","key":"54_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41409-019-0605-2","volume":"54","author":"M Lv","year":"2019","unstructured":"Lv M, Chang YJ, Huang XJ. Update of the \u201cBeijing Protocol\u201d haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(Suppl 2):703\u2013707.","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"54_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/bmt.2017.100","volume":"52","author":"R Zhang","year":"2017","unstructured":"Zhang R, Shi W, Wang HF, et al. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant. 2017;52(9):1253\u20131260.","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"54_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbmt.2018.07.021","volume":"25","author":"R Zhang","year":"2019","unstructured":"Zhang R, Lu X, Wang H, et al. Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25(1):47\u201355.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant."},{"key":"54_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.leukres.2016.04.014","volume":"46","author":"J Fang","year":"2016","unstructured":"Fang J, Zhang R, Wang H, et al. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Leuk Res. 2016;46:61\u201368.","journal-title":"Leuk Res."},{"issue":"2","key":"54_CR48","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/bmt.2011.66","volume":"47","author":"M Hong","year":"2012","unstructured":"Hong M, Wu Q, Hu C, et al. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone Marrow Transplant. 2012;47(2):196\u2013202.","journal-title":"Bone Marrow Transplant."},{"key":"54_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.844937","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Shi W, Lu X, et al. Decitabine-Intensified Modified Busulfan\/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis. Front Oncol. 2022;12:844937.","journal-title":"Front Oncol."},{"issue":"22","key":"54_CR50","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1182\/blood.2022016567","volume":"140","author":"S Loo","year":"2022","unstructured":"Loo S, Dillon R, Ivey A, et al. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood. 2022;140(22):2407\u20132411.","journal-title":"Blood."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00054-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00054-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:02:43Z","timestamp":1751875363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00054-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00054-y","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"type":"print","value":"2096-5230"},{"type":"electronic","value":"2523-899X"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This research was granted approval by the Ethical Committee of Wuhan Union Hospital in China, and all patients provided informed consent following institutional guidelines and the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}